Top

01-01-2015 | Renal cell carcinoma | Article

22. Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies

Authors: Christian Kollmannsberger, MD, FRCPC, G. A. Bjarnason, Alain Ravaud

Publisher: Springer International Publishing

Abstract

Targeted therapies have significantly changed the treatment landscape for patients with metastatic renal cell carcinoma (mRCC). TKIs such as sunitinib, sorafenib, pazopanib, and axitinib are all multi-targeted inhibitors which inhibit a variety of targets including the vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor (PDGFR), and others. Temsirolimus and everolimus both interfere with angiogenesis by inhibiting mTOR, a critical regulator within the cell. Bevacizumab blocks the vascular endothelial growth factor (VEGF) pathway by binding to VEGF.

Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef

Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068PubMedCrossRef

Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRef

Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23:1028–1043PubMedCrossRef

Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601–5608PubMedCrossRef

Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef

Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456PubMedCrossRef

Rini BI, Halabi S, Rosenberg JE et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28:2137–2143PubMedCentralPubMedCrossRef

Houk BE, Bello CL, Poland B et al (2009) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66:357–371PubMedCrossRef

10.

Amato RJ, Harris P, Dalton M et al (2007) A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 25(Suppl 18S):abstr 5026

11.

Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434PubMedCentralPubMedCrossRef

12.

Rini BI, Melichar B, Ueda T et al (2013) Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 14:1233–1242PubMedCentralPubMedCrossRef

13.

Escudier B, Szczylik C, Hutson TE et al (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280–1289PubMedCrossRef

14.

Boni JP, Leister C, Bender G et al (2005) Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 77:76–89PubMedCrossRef

15.

Lin Y, Ball HA, Suttle B et al (2011) Relationship between plasma pazopanib concentration and incidence of adverse events in renal cell carcinoma. J Clin Oncol 29(Suppl 7):abstr 345

16.

van der Veldt AA, Eechoute K, Gelderblom H et al (2011) Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 17:620–629PubMedCrossRef

17.

van Erp NP, Eechoute K, van der Veldt AA et al (2009) Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27:4406–4412PubMedCrossRef

18.

van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692–706PubMedCrossRef

19.

van Erp NP, Mathijssen RH, van der Veldt AA et al (2010) Myelosuppression by sunitinib is flt-3 genotype dependent. Br J Cancer 103:757–758PubMedCentralPubMedCrossRef

20.

Houk BE, Bello CL, Kang D et al (2009) A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 15:2497–2506PubMedCrossRef

21.

Rosen LS, Mulay M, Long J et al (2003) Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 22:abstr 765

22.

Maki RG, Fletcher JA, Heinrich MC et al (2005) Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 23:abstr 9011

23.

Atkinson BJ, Tannir NM, Jonasch E (2010) Schedule modifications and treatment outcomes for sunitinib-related adverse events. Am Soc Med Oncol Genitourin Cancers Symp 2010:abstr 357

24.

Bjarnason GA, Khalil B, Williams R et al (2011) Effect of an individualized dose/schedule strategy for sunitinib in metastatic renal cell cancer (mRCC) on progression-free survival (PFS): correlation with dynamic microbubble ultrasound (DCE-US) data. J Clin Oncol 29(Suppl 7):abstr 356

25.

Najjar YG, Mittal K, Elson P et al (2014) A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer 50:1084–1089PubMedCrossRef

26.

Atkinson BJ, Kalra S, Wang X et al (2014) Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol 191:611–618PubMedCentralPubMedCrossRef

27.

Motzer RJ, Basch E (2007) Targeted drugs for metastatic renal cell carcinoma. Lancet 370:2071–2073PubMedCrossRef

28.

Motzer RJ, Hudes GR, Curti BD et al (2007) Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 25:3958–3964PubMedCrossRef

29.

Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16–24PubMedCrossRef

30.

Motzer RJ, Hutson TE, Cella D, et al. (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722–731

31.

Kollmannsberger C, Bjarnason G, Burnett P et al (2011) Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist 16:543–553PubMedCentralPubMedCrossRef

32.

Minton O, Stone P, Richardson A et al (2008) Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev (1):CD006704

33.

Spence RR, Heesch KC, Brown WJ (2010) Exercise and cancer rehabilitation: a systematic review. Cancer Treat Rev 36:185–194PubMedCrossRef

34.

Gramignano G, Lusso MR, Madeddu C et al (2006) Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition 22:136–145PubMedCrossRef

35.

Sanchez-Barcelo EJ, Mediavilla MD, Tan DX et al (2010) Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 17:2070–2095PubMedCrossRef

36.

Barton DL, Soori GS, Bauer BA et al (2009) Pilot study of panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 18:179–187PubMedCentralPubMedCrossRef

37.

Rini BI, Tamaskar I, Shaheen P et al (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81–83PubMedCrossRef

38.

Desai J, Yassa L, Marqusee E et al (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660–664PubMedCrossRef

39.

Wolter P, Dumez H, Schoffski P (2007) Sunitinib and hypothyroidism. N Engl J Med 356:1580, author reply 1580-1PubMedCrossRef

40.

Wong E, Rosen LS, Mulay M et al (2007) Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351–355PubMedCrossRef

41.

Fujiwara Y, Kiyota N, Chayahara N et al (2012) Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs 30:1055–1064PubMedCentralPubMedCrossRef

42.

Wolter P, Stefan C, Decallonne B et al (2008) The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99:448–454PubMedCentralPubMedCrossRef

43.

Grossmann M, Premaratne E, Desai J et al (2008) Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 69:669–672CrossRef

44.

Mannavola D, Coco P, Vannucchi G et al (2007) A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531–3534PubMedCrossRef

45.

Schmidinger M, Vogl UM, Bojic M et al (2011) Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117:534–544PubMedCrossRef

46.

Baldazzi V, Tassi R, Lapini A et al (2012) The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol 30(5):704–710

47.

Rodondi N, den Elzen WP, Bauer DC et al (2010) Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 304:1365–1374PubMedCentralPubMedCrossRef

48.

Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35PubMedCrossRef

49.

Porta C, Paglino C, Imarisio I et al (2007) Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 7:127–134PubMedCrossRef

50.

Balagula Y, Wu S, Su X et al (2011) Hand-foot skin reaction, an anticipated dermatologic toxicity to pazopanib, with an unexpected low incidence: a systematic review of literature and meta-analysis. J Clin Oncol 29(Suppl 7):abstr 365

51.

Fischer A, Wu S, Ho AL et al (2013) The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 31:787–797PubMedCrossRef

52.

Beldner M, Jacobson M, Burges GE et al (2007) Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist 12:1178–1182PubMedCrossRef

53.

Suwattee P, Chow S, Berg BC et al (2008) Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol 144:123–125PubMedCrossRef

54.

Lacouture ME, Reilly LM, Gerami P et al (2008) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19:1955–1961PubMedCrossRef

55.

Yang CH, Lin WC, Chuang CK et al (2008) Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 158:592–596PubMedCrossRef

56.

Jacobi U, Waibler E, Schulze P et al (2005) Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 16:1210–1211PubMedCrossRef

57.

Rouffiac V, Bouquet C, Lassau N et al (2004) Validation of a new method for quantifying in vivo murine tumor necrosis by sonography. Invest Radiol 39:350–356PubMedCrossRef

58.

Erber R, Thurnher A, Katsen AD et al (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338–340PubMed

59.

Tsai KY, Yang CH, Kuo TT et al (2006) Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 24:5786–5788PubMedCrossRef

60.

Robert C, Soria JC, Spatz A et al (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491–500PubMedCrossRef

61.

Sheen YS, Huang CL, Chu CY (2007) Eccrine squamous syringometaplasia associated with sunitinib therapy. J Eur Acad Dermatol Venereol 21:1136–1137PubMedCrossRef

62.

Thompson DS, Greco FA, Spigel DR et al (2006) Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: update of a multicenter phase II trial. Proc Am Soc Clin Oncol 24:abstr 4594

63.

Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516–2524PubMedCrossRef

64.

Alexandrescu DT, Vaillant JG, Dasanu CA (2007) Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol 32:71–74PubMed

65.

Taichman NS, Cruchley AT, Fletcher LM et al (1998) Vascular endothelial growth factor in normal human salivary glands and saliva: a possible role in the maintenance of mucosal homeostasis. Lab Invest 78:869–875PubMed

66.

Rubenstein EB, Peterson DE, Schubert M et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046PubMedCrossRef

67.

Lordick F, Geinitz H, Theisen J et al (2006) Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 64:1295–1298PubMedCrossRef

68.

Gore ME, Szczylik C, Porta C et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10:757–763PubMedCrossRef

69.

Bellmunt J, Szczylik C, Feingold J et al (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19:1387–1392PubMedCrossRef

70.

Lee S, Chung H-C, Mainwaring P et al (2009) An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma. Eur J Cancer Suppl 7:428CrossRef

71.

Lammie A, Drobnjak M, Gerald W et al (1994) Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 42:1417–1425PubMedCrossRef

72.

Sica DA (2006) Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 24:1329–1331PubMedCrossRef

73.

Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–147PubMedCentralPubMedCrossRef

74.

Ahmad T, Eisen T (2004) Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10:6388S–6392SPubMedCrossRef

75.

Maitland ML, Bakris GL, Black HR et al (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:596–604PubMedCentralPubMedCrossRef

76.

Veronese ML, Mosenkis A, Flaherty KT et al (2006) Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24:1363–1369PubMedCrossRef

77.

Robinson ES, Khankin EV, Choueiri TK et al (2010) Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 56:1131–1136PubMedCentralPubMedCrossRef

78.

Kappers MH, de Beer VJ, Zhou Z et al (2012) Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 59:151–157PubMedCrossRef

79.

Rini BI, Cohen DP, Lu DR et al (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763–773PubMedCentralPubMedCrossRef

80.

Hackam DG, Khan NA, Hemmelgarn BR et al (2010) The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 – therapy. Can J Cardiol 26:249–258PubMedCentralPubMedCrossRef

81.

Chobanian AV, Bakris GL, Black HR et al (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560–2572PubMedCrossRef

82.

Richards CJ, Je Y, Schutz FA et al (2011) Incidence and risk of congestive heart failure risk in renal cell cancer (RCC) and non-RCC patients treated with sunitinib. J Clin Oncol 29(Suppl 7):abstr 316

83.

Hall PS, Harshman LC, Srinivas S et al (2013) The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail 1:72–78PubMedCrossRef

84.

Force T, Kolaja KL (2011) Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov 10:111–126PubMedCrossRef

85.

Bamias A, Lainakis G, Manios E et al (2009) Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors? J Clin Oncol 27:2567–2569, author reply 2569-70PubMedCrossRef

86.

Chu TF, Rupnick MA, Kerkela R et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011–2019PubMedCentralPubMedCrossRef

87.

Izumiya Y, Shiojima I, Sato K et al (2006) Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 47:887–893PubMedCentralPubMedCrossRef

88.

Chintalgattu V, Ai D, Langley RR et al (2010) Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest 120:472–484PubMedCentralPubMedCrossRef

89.

Orphanos GS, Ioannidis GN, Ardavanis AG (2009) Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 48:964–970PubMedCrossRef

90.

Kerkela R, Woulfe KC, Durand JB et al (2009) Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2:15–25PubMedCentralPubMedCrossRef

91.

Cheng H, Force T (2010) Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis 53:114–120PubMedCrossRef

92.

French KJ, Coatney RW, Renninger JP et al (2010) Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity. Toxicol Pathol 38:691–702PubMedCrossRef

93.

Szmit S, Nurzynski P, Szalus N et al (2009) Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib. Acta Oncol 48:921–925PubMedCrossRef

94.

Schmidinger M, Bojic A, Vogl UM et al (2009) Management of cardiac adverse events occurring with sunitinib treatment. Anticancer Res 29:1627–1629PubMed

95.

Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332–344PubMedCrossRef

96.

Maroto JP, Hudes G, Dutcher JP et al (2011) Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 29:1750–1756PubMedCrossRef

97.

White DA, Camus P, Endo M et al (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182:396–403PubMedCrossRef

98.

Atkinson BJ, Cauley DH, Ng C et al (2014) Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int 113:376–382PubMedCentralPubMedCrossRef

99.

De Simone P, Petruccelli S, Precisi A et al (2007) Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient–not all proliferation signal inhibitors are the same: a case report. Transplant Proc 39:3500–3501PubMedCrossRef

100.

Je Y, Schutz FAB, Choueiri TK (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 10:967–974PubMedCrossRef

101.

Khan G, Golshayan A, Elson P et al (2010) Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol 21:1618–1622PubMedCrossRef

102.

Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48:9–17PubMedCrossRef

103.

Rodbard HW, Blonde L, Braithwaite SS et al (2007) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13(Suppl 1):1–68PubMedCrossRef

104.

Grundy SM, Cleeman JI, Merz CN et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44:720–732PubMedCrossRef

105.

Shah RR, Morganroth J, Shah DR (2013) Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 36:491–503PubMedCrossRef

106.

Teo YL, Ho HK, Chan A (2013) Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat Rev 39:199–206PubMedCrossRef

107.

GlaxoSmithKline: Votrient (pazopanib) tablets: full prescribing information (2010) GlaxoSmithKline, Research Triangle Park

108.

Mueller EW, Rockey ML, Rashkin MC (2008) Sunitinib-related fulminant hepatic failure: case report and review of the literature. Pharmacotherapy 28:1066–1070PubMedCrossRef

109.

Xu CF, Reck BH, Xue Z et al (2010) Pazopanib-induced hyperbilirubinemia is associated with Gilbert’s syndrome UGT1A1 polymorphism. Br J Cancer 102:1371–1377PubMedCentralPubMedCrossRef

110.

Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–4265PubMedCrossRef

111.

Khambati H, Choueiri TK, Kollmannsberger C et al (2011) Efficacy of targeted drug therapy for metastatic renal cell carcinoma in the elderly patient population. J Clin Oncol 29(Suppl 7):abstr 318

» This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Medicine Matters Oncology

Abstract